BRCA1 and pancreatic neoplasm: Recently the results of a multicenter phase II study confirmed that encouraging responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations including breast, ovarian, prostate, and pancreatic cancer who received prior chemotherapies, and AEs most frequently reported were fatigue, nausea, and vomiting [60].